A Crystal Ball for Cancer Survivors

Circulating tumor DNA (ctDNA) tests can predict near-certainly the recurrence of cancer in survivors in the US. In patients with minimal residual disease, ctDNA blood tests can foresee whether the cancer will reoccur, an outcome linked to a near 100% chance of relapse. Furthermore, the ctDNA test can inform adjuvant therapy decisions. However, testing is not available to all patients as both the National Comprehensive Cancer Network and the American Society of Clinical Oncology do not endorse the testing due to a lack of proof of clinical utility.